Contineum therapeutics provides update on phase 1b positron emission tomography (pet) trial of pipe-791

San diego--(business wire)--contineum therapeutics, inc. (nasdaq: ctnm) (contineum or the company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (ni&i) indications, today announced an update on its phase 1b positron emission tomography (pet) trial of pipe-791, a selective antagonist of the lysophosphatidic acid 1 (lpa1) receptor. the company has completed enrollment of the healthy volunteer and.
PET Ratings Summary
PET Quant Ranking